Core Points - Enanta Pharmaceuticals announced the top line results of their RSVHR study, which was made available in a news release [2] - The conference call included key executives such as the President and CEO, Chief Medical Officer, and Chief Product Strategy Officer [3] Company Information - The conference call is being recorded and is accessible via webcast with accompanying slides available on the company's website [1][2] - The company emphasizes that forward-looking statements regarding their research and development pipeline and financial projections may involve risks and assumptions that could lead to different outcomes [4]

Core Points - Enanta Pharmaceuticals announced the top line results of their RSVHR study, which was made available in a news release [2] - The conference call included key executives such as the President and CEO, Chief Medical Officer, and Chief Product Strategy Officer [3] Company Information - The call was led by Jennifer Viera, who is the Executive Director of Investor Relations and Corporate Communications [2] - The conference call is being webcast and includes slides that are accessible on the company's website [2] Forward-Looking Statements - The company reminded participants that forward-looking statements will be made regarding their research and development pipeline and financial projections, which involve assumptions and risks [4]